Molecular targeted therapy for non-small cell lung cancer and drug resistance

doi:10.3760/cma.j.issn.1673-422X.2016.01.013

Abstract

Abstract: Gefitinib and erlotinib play important roles, which as the representative of the epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). However, preclinical and clinical studies find that many patients exist primary or acquired drug resistance to this drug, which limits the use of molecular targeted therapy drugs. At present, there are many studies focus on delaying or reversing drug resistance and developing new targets, which provide more potential for the molecular targeted therapy of NSCLC.

Key words: Carcinoma, non-small-cell lung, Mutation, Receptor, epidermal growth factor, Drug resistance, neoplasm, Molecular targeted therapy

Zhang Yu, Zhou Jianguo, Ma Hu. Molecular targeted therapy for non-small cell lung cancer and drug resistance[J]. Journal of International Oncology, 2016, 43(1): 45-48.

References

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI:10.3322/caac.21254. ［2］ Jiang T, Zhou C. Clinical activity of the mutantselective EGFR inhibitor AZD9291 in patients with EGFR inhibitorresistant nonsmall cell lung cancer［J］. Transl Lung Cancer Res, 2014, 32(6): 8009. DOI:10.3978/j.issn.22186751.2014.08.02. ［3］ Wakelee H. ELCC 2014 news: phase Ⅰ study of CO1686 in patients with EGFR mutated recurrent, advanced NSCLC［C］. Switzerland, ELCC, 2014. ［4］ Sequist LV, Yang JC, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations［J］. J Clin Oncol, 2013, 31(27): 3327-3334. ［5］ Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in nonsmallcell lung cancer［J］. Nature, 2007, 448(7153): 561-563. ［6］ Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmallcell lung cancer［J］. N Engl J Med, 2010, 363(18): 16931703. DOI:10.1056/NEJMoa1006448. ［7］ Solomon BJ, Gettinger SN, Riely GJ, et al. Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase Ⅲ study (PROFILE 1007) of advanced ALKpositive nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2013, 31 suppl: abstr 8105. ［8］ Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFRmutant lung cancer by activation of Akt and EGFR［J］. Cancer Res, 2009, 69(8): 3256-3261. ［9］ Chang TH, Tsai MF, Su KY, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor［J］. Am J Respir Crit Care Med, 2011, 183(8): 1071-1079. DOI:10.1164/rccm.201009-1440OC. ［10］ Winn RA, Tuder RM. "Unslugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy［J］. Am J Respir Crit Care Med, 2011, 183(8): 970972. DOI: 10.1164/rccm.2010121970ED. ［11］ Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases［J］. Clin Cancer Res, 2009, 15(14): 45544560. DOI:10.1158/1078-0432.CCR-09-0089. ［12］ Blumenschein GR, Smit EF, Planchard DA, et al. MEK114653: a randomized, multicenter, phase Ⅱ study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRASmutant advanced nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2013, 31 Suppl: abstr 8029. ［13］ Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4ALK fusion oncogene［J］. Cancer Res, 2010, 70(23): 9827-9836. DOI:10.1158/0008-5472.CAN-10-1671. ［14］ Sasaki T, Jnne PA. New strategies for treatment of ALKrearranged nonsmall cell lung cancers［J］. Clin Cancer Res, 2011, 17(23): 7213-7218. DOI:10.1158/1078-0432.CCR-11-1404. ［15］ Wang M, Zhao J, Zhang LM, et al. Combined erlotinib and cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non- ［16］ Yamamoto N, Murakami H, Takahashi T, et al. Final results of a Japanese phase 1 trial evaluating a cmet inhibitor tivantinib in combination with an EGFR inhibitor erlotinib in advanced/metastatic nonsmall cell lung cancer (ARQ 197003/005 study)［J］. Ann Oncol, 2012, 23: 424. ［17］ Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced nonsmallcell lung cancer: a phase Ⅲ trial［J］. J Clin Oncol, 2012, 30(17): 20702078. DOI:10.1200/JCO.2011.39.2993. ［18］ VarellaGarcia M, Xu LG, Mahale SA,, et al. Nonsmallcell lung cancer: molecular targeted therapy and personalized medicine drug resistance, mechanisms, and strategies［J］. Pharmgenomics Pers Med, 2013, 6: 2536. DOI:10.2147/PGPM.S26058. ［19］ Garcia MV, Xu LG, Mahale S, et al. RET rearrangements detected by FISH in "pannegative" lung adenocarcinoma［J］. J Clin Oncol, 2013, 31 Suppl: abstr 8024.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[5]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[6]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[7]	Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin. Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(5): 263-267.
[8]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[9]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[10]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[11]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui. Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(12): 758-762.
[12]	Jiang Shan, Xu Ximing. Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(11): 688-695.
[13]	Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing. Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy [J]. Journal of International Oncology, 2023, 50(10): 600-607.
[14]	Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation [J]. Journal of International Oncology, 2023, 50(1): 37-41.
[15]	Song Jia, Hu Qinyong. Application of TACE combined with molecular targeted therapy and immunotherapy in BCLC B/C hepatocellular carcinoma [J]. Journal of International Oncology, 2022, 49(9): 550-554.